Oncolytics Advances Pelareorep Toward Anal Cancer Approval
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
DENVER, USA – March 18, 2026 TriSalus Life Sciences has announced new preclinical findings demonstrating that its Pressure-Enabled Drug...
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
SYDNEY, Dec. 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) unveiled compelling clinical and translational data highlighting the ability...
October 14, 2025 | Düsseldorf, Germany — Abalos Therapeutics announced the publication of preclinical proof-of-concept data in Cell Reports...
BRONX, NY, Oct. 3, 2025 — Researchers at Montefiore Einstein and Albert Einstein College of Medicine reveal that glioblastoma...
